Compare GXAI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | SNGX |
|---|---|---|
| Founded | 2021 | 1987 |
| Country | United States | United States |
| Employees | 3 | 14 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 8.2M |
| IPO Year | 2022 | 2006 |
| Metric | GXAI | SNGX |
|---|---|---|
| Price | $0.58 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 227.0K | 225.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,933,030.00 | $119,371.00 |
| Revenue This Year | $271.23 | N/A |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.51 | $0.28 |
| 52 Week High | $2.63 | $1.97 |
| Indicator | GXAI | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.97 |
| Support Level | N/A | $0.35 |
| Resistance Level | N/A | $0.42 |
| Average True Range (ATR) | 0.00 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 66.67 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).